The MOPETT Trial took sub-massive PE patients and randomized them to half-dose tPA vs. standard care. No bleeds in either group. 41% ARR of pulmonary hypertension at 28 months.
Study Description from the Author
Does this change your game?
A new trial using a similar protocol showed benefit without complications (Clinical Cardiology Volume 37, Issue 2, pages 78–82, February 2014)
- EMCrit 303 – A Bounceback Case with Mike Weinstock - July 23, 2021
- EMCrit 302 – Pain Management Update with Sergey Motov - July 15, 2021
- EMCrit 301 – The Five Fears with Rob Orman (Mind of the Resuscitationist) - July 1, 2021